Efficacy of Highly Selective-a-1A-Adrenoceptor Antagonist Silodosin in Expulsive Therapy of Lower Ureteral Stones: A Randomized Controlled Study

Efficacy of highly selective-a-1A-adrenoceptor antagonist in expulsive therapy of lower ureteral stones

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000571976

Enrollment

Registered

2011-06-03

Start date

2010-10-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

a comparative study to evaluate the clinical role of highly selective a-1A blocker in the medical expulsive therapy of symptomatic lower ureteral stones.

Interventions

orally highly selective a-1A blocker(silodosin 4 mg and tamsulosin 0.2 mg) once daily for 2 weeks

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Healthy volunteers

Inclusion criteria

symptomatic radiopaque lower ureteral stones >5mm aged between 20 and 60 years old

Exclusion criteria

Subjects with urinary tract infections, high-grade hydronephrosis, diabetes, ulcers, or a history of hypersensitivity toa-1 blocker and pregnant women were excluded. Patients with a history of spontaneous stone expulsion, hypotension, or those found to have systolic blood pressure lower than 110 mmHg were also excluded.

Outcome results